Long-suffering biotech investors might be in for a treat as the SPDR S&P Biotech exchange begins to show signs of renewed ...

Biotech stumbled in FY25, but we didn’t. HB Biotechnology kept its footing and delivered 23% outperformance in a tough market ...

Ultragenyx and partner Mereo BioPharma’s brittle bone disease trial will continue. Investors had wanted data good enough to ...

In this article, we discuss the 12 best biotech stocks to buy under $10. If you want to see more stocks in this selection, check out 5 Best Biotech Stocks To Buy Under $10. The past two years have ...

Here is STAT’s biotech scorecard, our regular ledger of stock-moving biotech events, for the third quarter: MoonLake ...

Each of these biotech stocks has real potential to tackle other health-related issues, some of which have plagued us for centuries. 7 Retail Stocks That You Don't Want In Your Cart ...

Glenmark Pharmaceuticals Ltd.’s licensing pact with AbbVie Inc. for its blood cancer drug is boosting optimism over Indian ...

Biotech stocks are not for the faint of heart. These highly volatile equities can see stomach-churning price swings, driven by how their treatments fare in Food & Drug Administration clinical ...

Should Investors Be Watching these Top Biotech Stocks Right Now?As we approach the end of 2021, it seems that biotech stocks could continue to make viable plays in the stock market. This can be ...

U.K. biotech stock Myovant Sciences (MYOV, $22.60) is one such firm. The key to that focus is MYOV compound Relugolix. The drug has already been approved for treating certain prostate cancers.

The move higher in biotech stocks comes after a rough start in the first half of the year, when the biotech index lost 17.7%, more than it lost in the first six months of any year since 2016.